Organ preservation following short-course radiotherapy for rectal cancer

被引:15
作者
Nilsson, Per J. [1 ,2 ]
Ahlberg, Madelene [1 ]
Kordnejad, Shahrzad [1 ]
Holm, Torbjorn [3 ]
Martling, Anna [1 ,2 ]
机构
[1] Karolinska Univ Hosp, Div Coloproctol, Dept Pelv Canc, Anna Stecksens Gata 30A, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[3] Soder Sjukhuset, Dept Surg, Stockholm, Sweden
来源
BJS OPEN | 2021年 / 5卷 / 05期
关键词
TOTAL MESORECTAL EXCISION; CLINICAL COMPLETE RESPONDERS; PREOPERATIVE RADIOTHERAPY; OPEN-LABEL; NEOADJUVANT CHEMORADIOTHERAPY; INTERNATIONAL WATCH; WAIT DATABASE; MULTICENTER; SURGERY; CHEMOTHERAPY;
D O I
10.1093/bjsopen/zrab093
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Non-operative management of rectal cancer is increasingly being used in selected patients. Most reports include patients treated with chemoradiotherapy (CRT) before inclusion into a Watch & Wait (W&W) programme. The aim of this study was to report outcomes from a single-centre W&W programme involving a large cohort of patients. Methods: Patients treated with chemoradiotherapy (CRT) or short-course radiotherapy (SCRT) with or without chemotherapy, between 2008 and 2020, who showed signs of a clinical complete response (cCR) were reviewed. Patients were assessed using digital rectal examination, flexible endoscopy, carcinoembryonic antigen measurement, MRI, and CT imaging, discussed at the multidisciplinary tumour board meeting, and followed up in a dedicated W&W programme as from 2015. Outcomes including regrowth and 3-year survival (time to regrowth or death) were prospectively evaluated. Results: Of 142 patients who were assessed, 88 fulfilled the criteria for cCR. Treatment before cCR included CRT, SCRT with chemotherapy, and SCRT alone in 16 (18 per cent), 28 (32 per cent), and 44 (50 per cent) patients, respectively. Patients treated with CRT and SCRT with chemotherapy had more advanced clinical T- and N-stage, compared with patients treated with SCRT alone (clinical T- stage> 2: 81 per cent and 89 per cent versus 47 per cent, respectively; clinical N-stage > 0: 75 per cent and 93 per cent versus 68 per cent, respectively). Overall rate of regrowth was 19 per cent, with 31 per cent, 21 per cent, and 14 per cent following CRT, SCRT with chemotherapy, and SCRT alone, respectively. Uni- and multivariable analyses evaluating the clinical parameters revealed no statistically significant associations with risk of local regrowth. All but one patient with regrowth underwent salvage surgery. The 3-year survival rate (death with regrowth as competing risk) was 93 per cent, with no significant difference between treatment groups. Conclusion: In this cohort of W&W patients, the vast majority received SCRT with or without chemotherapy and results consistent with previous W&W reports were obtained. No statistically significant differences in terms of regrowth rate were obtained when comparing CRT, SCRT with chemotherapy, and SCRT alone. SCRT can induce sustained cCR and may precede a W&W strategy.
引用
收藏
页数:7
相关论文
共 20 条
  • [1] Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study
    Bach, Simon P.
    Gilbert, Alexandra
    Brock, Kristian
    Korsgen, Stephan
    Geh, Ian
    Hill, James
    Gill, Talvinder
    Hainsworth, Paul
    Tutton, Matthew G.
    Khan, Jim
    Robinson, Jonathan
    Steward, Mark
    Cunningham, Christopher
    Levy, Bruce
    Beveridge, Alan
    Handley, Kelly
    Kaur, Manjinder
    Marchevsky, Natalie
    Magill, Laura
    Russell, Ann
    Quirke, Philip
    West, Nicholas P.
    Sebag-Montefiore, David
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (02): : 92 - 105
  • [2] Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
    Bahadoer, Renu R.
    Dijkstra, Esmee A.
    van Etten, Boudewijn
    Marijnen, Corrie A. M.
    Putter, Hein
    Kranenbarg, Elma Meershoek-Klein
    Roodvoets, Annet G. H.
    Nagtegaal, Iris D.
    Beets-Tan, Regina G. H.
    Blomqvist, Lennart K.
    Fokstuen, Tone
    ten Tije, Albert J.
    Capdevila, Jaume
    Hendriks, Mathijs P.
    Edhemovic, Ibrahim
    Cervantes, Andres
    Nilsson, Per J.
    Glimelius, Bengt
    van de Velde, Cornelis J. H.
    Hospers, Geke A. P.
    [J]. LANCET ONCOLOGY, 2021, 22 (01) : 29 - 42
  • [3] Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study
    Braendengen, Morten
    Tveit, Kjell M.
    Hjermstad, Marianne J.
    Johansson, Hemming
    Berglund, Ake
    Brandberg, Yvonne
    Glimelius, Bengt
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (06) : 813 - 819
  • [4] Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial
    Erlandsson, Johan
    Holm, Torbjorn
    Pettersson, David
    Berglund, Ake
    Cedermark, Bjorn
    Radu, Calin
    Johansson, Hemming
    Machado, Mikael
    Hjern, Fredrik
    Hallbook, Olof
    Syk, Ingvar
    Glimelius, Bengt
    Martling, Anna
    [J]. LANCET ONCOLOGY, 2017, 18 (03) : 336 - 346
  • [5] Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study
    Fernandez, Laura M.
    Sao Juliao, Guilherme P.
    Figueiredo, Nuno L.
    Beets, Geerard L.
    van der Valk, Maxime J. M.
    Bahadoer, Renu R.
    Hilling, Denise E.
    Kranenbarg, Elma Meershoek-Klein
    Roodvoets, Annet G. H.
    Renehan, Andrew G.
    van de Velde, Cornelis J. H.
    Habr-Gama, Angelita
    Perez, Rodrigo O.
    [J]. LANCET ONCOLOGY, 2021, 22 (01) : 43 - 50
  • [6] Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial
    Garcia-Aguilar, Julio
    Renfro, Lindsay A.
    Chow, Oliver S.
    Shi, Qian
    Carrero, Xiomara W.
    Lynn, Patricio B.
    Thomas, Charles R., Jr.
    Chan, Emily
    Cataldo, Peter A.
    Marcet, Jorge E.
    Medich, David S.
    Johnson, Craig S.
    Oommen, Samuel C.
    Wolff, Bruce G.
    Pigazzi, Alessio
    McNevin, Shane M.
    Pons, Roger K.
    Bleday, Ronald
    [J]. LANCET ONCOLOGY, 2015, 16 (15) : 1537 - 1546
  • [7] Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial
    Garcia-Aguilar, Julio
    Chow, Oliver S.
    Smith, David D.
    Marcet, Jorge E.
    Cataldo, Peter A.
    Varma, Madhulika G.
    Kumar, Anjali S.
    Oommen, Samuel
    Coutsoftides, Theodore
    Hunt, Steven R.
    Stamos, Michael J.
    Ternent, Charles A.
    Herzig, Daniel O.
    Fichera, Alessandro
    Polite, Blase N.
    Dietz, David W.
    Patil, Sujata
    Avila, Karin
    [J]. LANCET ONCOLOGY, 2015, 16 (08) : 957 - 966
  • [8] Is watch and wait a safe and effective way to treat rectal cancer in older patients?
    Haak, Hester E.
    Maas, Monique
    Lambregts, Doenja M. J.
    Beets-Tan, Regina G. H.
    Beets, Geerard L.
    [J]. EJSO, 2020, 46 (03): : 358 - 362
  • [9] Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy - Long-term results
    Habr-Gama, A
    Perez, RO
    Nadalin, W
    Sabbaga, J
    Ribeiro, U
    Sousa, AHSE
    Campos, FG
    Kiss, DR
    Gama-Rodrigues, J
    [J]. ANNALS OF SURGERY, 2004, 240 (04) : 711 - 717
  • [10] Organ Preservation in cT2N0 Rectal Cancer After Neoadjuvant Chemoradiation Therapy The Impact of Radiation Therapy Dose-escalation and Consolidation Chemotherapy
    Habr-Gama, Angelita
    Sao Juliao, Guilherme Pagin
    Vailati, Bruna Borba
    Sabbaga, Jorge
    Aguilar, Patricia Bailao
    Fernandez, Laura Melina
    Alonso Araujo, Sergio Eduardo
    Perez, Rodrigo Oliva
    [J]. ANNALS OF SURGERY, 2019, 269 (01) : 102 - 107